GEN Exclusives

More »

GEN News Highlights

More »
Nov 30, 2011

Nearly Two-to-One Majority Sees FDA or EMA Approval of Gene Therapy by 2013

  • A gene therapy will receive either FDA or EMA approval in the next two years, according to a nearly two-to-one majority in our poll.Of those who voted, 61.4% see rapid growth for gene therapy, while 32.9% do not believe a gene therapy will reach the market by 2013, and 5.7% were undecided about the fate of this segment.

    One report predicts the market will grow to $316 million by 2015, driven by high demand. Yet while the science behind gene therapy has come a long way, proving efficacy and navigating the regulatory pathway remain roadblocks. Most recently, for example,  EMA’s Committee for Medicinal Products for Human Use recommend that Amsterdam Molecular Therapeutics' (AMT's) gene therapy Glybera should not be approved for lipoprotein lipase deficiency. Had AMT received the green light for Glybera, it would have become the first gene therapy approved outside of China.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?